Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Miniaturized technology for protein and nucleic acid point-of-care testing

FELIX OLASAGASTI, and JUAN CARLOS RUIZ DE GORDOA

VITORIA-GASTEIZ, SPAIN

The field of point-of-care (POC) testing technology is developing quickly and producing instruments that are increasingly reliable, while their size is being gradually reduced. Proteins are a common target for POC analyses and the detection of protein markers typically involves immunoassays aimed at detecting different groups of proteins such as tumor markers, inflammation proteins, and cardiac markers; but other techniques can also be used to analyze plasma proteins. In the case of nucleic acids, hybridization and amplification strategies can be used to record electromagnetic or electric signals. These techniques allow for the identification of specific viral or bacterial infections as well as specific cancers. In this review, we consider some of the latest advances in the analysis of specific nucleic acid and protein biomarkers, taking into account their trend toward miniaturization and paying special attention to the technology that can be implemented in future applications, such as lab-on-a-chip instruments. (Translational Research 2012;160:332–345)

Abbreviations: POC = point-of-care; LFI = lateral flow immunochromatography; PSA = prostate-specific antigen; hCG = human chorionic gonadotropin; TSH = thyroid-stimulating hormone; SEB = staphylococcal enterotoxin B; FRET = Förster resonance energy transfer; MMP = matrix metalloproteinase; BNP = B-type natriuretic peptide; CRP = C-reactive protein; PDMS = polydimethylsiloxane; Ig = Immunoglobulin; HbA1c = hemoglobin A1c; Ag = antigen; Ab = antibody; TNFa = tumor necrosis factor; PCT = procalcitonin; IL = Interleukin; PCR = polymerase chain reaction; CA = cancer antigen; CEA = carcinoembryonic antigen; NMP = nuclear matrix protein; 1,25(OH)2 = 1,25-dihydroxyvitamin D; ELISA = enzyme-linked immunosorbent assay; VEGF = vascular endothelial growth factor; PMMA = polymethylmethacrylate; cTnI = cardiac troponin I; EGF = epidermal growth factor; IP = interferon-induced; MCP = monocyte chemoattractant protein; Timp-1 = tissue inhibitor of matrix metalloproteinase-1; RANTES = regulated upon activation, normal T cell expressed and secreted; MIP-1 = macrophage inflammatory protein-beta; cTnT = cardiac troponin T; HRP = horseradish peroxidase; SiFET = silicon field-effect-transistor; APC = allophycocyanin; HE4 = human epididymis protein 4; TMB = 3,3’,5,5’-tetramethylbenzidine; hp = hairpin; LAMP = loop-mediated isothermal amplification; mLAMP = multiplex microfluidic LAMP; HAD = helicase-dependent amplification; NASBA = nucleic acid sequence based amplification; LFM = lateral flow chromatography microarrays; HSP = heat shock proteins; SPR = surface plasmon resonance; MEMS = micro-electro-mechanical systems; MIMED = magnetic integrated microfluidic electrochemical detectors
The field of point-of-care (POC) testing technology is developing quickly and producing instruments that are increasingly reliable, while their size is being gradually reduced. In this review, we consider some of the most recent advances in the analysis of specific nucleic acid and protein biomarkers, paying special attention to the analytical techniques that can be accomplished by current and future miniaturized devices.

ANALYSIS OF PROTEINS

Proteins are a common target for many POC analysis methods (see Table I). They can be detected and quantified in a number of ways, but lateral flow immunochromatography (LFI) is the most common detection method due to its specificity. The following are some examples of this and other techniques currently under development for POC applications.

Lateral flow immunochromatography. Currently, most commercially available devices are based on LFI. The assays are conducted on paper, nitrocellulose or plastic supports. The analyte migrates up the support by capillarity, along with the appropriately-conjugated antibodies, up to a test zone where another antibody immobilizes the complex. A second antibody binds to the analyte, which is then sandwiched between the 2 antibodies. The conjugated antibody that did not initially bind to the analyte continues migrating up to a third antibody that binds it within a control zone. To detect the complex that is formed with the analytes, the first antibody is usually bound to markers such as colloidal gold particles, colored latex, or selenium, depending on the kind of detector used. As a result, qualitative or quantitative measures are typically obtained within 15 min.

Many of these detectors are based on reflectometry and measure visible light. The analytical devices can be designed for a single-strip test or for multiple analytes. Blood is the most common source of samples for analysis, and instruments often include a wicking pad to separate plasma from whole blood.

The portable LFI can also be used for urine samples. Some examples include the detection of anti- Helicobacter pylori IgG, as well as the bladder cancer tumor marker NMP22 (nuclear matrix protein). There is a wide spectrum of commercial LFI POC devices designed for the detection of antigens related to infectious diseases, inflammation and sepsis proteins (such as C-reactive protein [CRP] or procalcitonin [PCT]), cardiac markers (creatine kinase isoenzyme MB, troponins, B-type natriuretic peptide, or myoglobin), tumor markers (prostate specific antigen [PSA]), glycosilated hemoglobin, and some hormones (such as human chorionic gonadotropin [hCG] or thyroid-stimulating hormone [TSH]). These devices use different markers for the detection of the first binding antibody. Among them, fluorescent markers are most popular because they provide good sensitivity for analysis.

An example of this strategy is the work of Ahn et al., who used a fluorescence scanner to measure CRP. These authors obtained a limit of detection of 0.133 mcg/mL with good precision (CV < 10%) and good correlation with the reference method based on immunoturbidimetry. A similar approach was used by Meagher et al who designed a portable device for the detection of biotins. Their quick (less than 20 min) microfluidic chip-based immunoassay was tested in ricin, Staphylococcal enterotoxin B (SEB). The limit of detection for SEB was 300 pm, which was reduced to 10 pm when adding a pre-concentration step on the chip. Herr et al designed an even faster assay to identify periodontitis populations in less than 20 microliters. They could detect collagen-cleaving enzyme matrix metalloproteinase-8 (MMP-8) in less than 2 min.

The last 2 examples illustrate that many of the instruments developed for POC applications must account for the need to use small sample amounts. As a result, research or commercial applications often include complex microfluidic systems. These systems contain microcapillaries that allow the flow of very small liquid volumes. Plasma can separate from the blood sample through a filter and reach the reaction chamber, where it meets fluorescent antibodies. The analytes are detected as antigen-antibody complexes, which move toward an antibody array where they are distributed according to different capture antibodies. The concentration of each analyte is measured from the Förster resonance energy transfer (FRET) fluorescence, in which fluorescence results from a distance-dependent interaction between an electron donor and an acceptor, with excitation wavelengths close to infra-red, as appropriate for plasma and serum samples.

A clinical evaluation of this type of system was carried out with a commercial device, which incorporated 4 biomarkers related to brain ischemia (matrix metalloproteinase 9, D-dimer, S100B, and B-type natriuretic peptide) to evaluate the existence of a stroke in patients who showed related neurological symptoms. Authors concluded that although the diagnosis was not perfect with these tests (the area under the receiver-operating-characteristic curve was 0.76 for hemorrhagic stroke and 0.69 for all strokes): they do aid in forming a diagnostic picture when they are applied together with other tests.

Microfluidic schemes can also be used, for instance, for the analysis of CRP in human serum. This method compares well with the reference enzyme-linked
| Tested target | Relevance of sample* | Detection strategy | Sensitivity/Limit of detection (LOD)† | Timeframe | Ref. |
|---------------|----------------------|--------------------|--------------------------------------|-----------|-----|
| Lateral flow immunoassays | | | | | |
| Thyroid-stimulating hormone (TSH) and human chorionic gonadotropin (hCG) | Whole blood and plasma | Piezofilm sensor | LOD: 18 pg/mL for TSH | 5–10 min | (7) |
| C reactive protein (CRP) | Whole blood | Fluorescence (in plastic disposable cartridge) | LOD: 133 ng/mL | 10 min | (5) |
| Biotoxins ricin, Shiga toxin I and Staphylococcal enterotoxin B | Biological toxins | Fluorescence (Microfluidic with polyacrylamide electrophoresis) | LOD: 20 nM for ricin; 500 pM for Shiga toxin I; 300 pM for Staphylococcal enterotoxin B | Incubation Ag-Ab: 30 min; Electrophoresis: 3 min | (9) |
| Matrix metalloproteinase-8 (MMP-8) | Saliva | Fluorescence (Microfluidic with polyacrylamide electrophoresis) | LOD: 130 ng/mL | 2 min | (10) |
| CRP | Serum | Chemiluminescence (Microfluidic channels) | Linear range: 2–15 μg/mL | 26 min | (15) |
| CRP | Serum and cerebrospinal fluid | Fluorescence (Microfluidic capillary system for immunoaffinity chromatography) | Calibration ranges: 0.05–3.0 μg/mL for 1:10 diluted serum; 0.01–30 for undiluted cerebrospinal fluid | 10 min | (16) |
| CRP | Serum | Fluorescence (Microfluidic on PDMS) | LOD: 10 ng/mL | <3 min | (17) |
| CRP-enriched human serum | Fluorescence (Microfluidic on PDMS) | LOD: 0.42 nM | 20 min | (18) |
| Vascular endothelial growth factor (VEGF) | Human plasma | Fluorescence (Elastomeric microfluidic chip) | LOD: 4 pM | ~10 min | (19) |
| CRP and ferritin | Serum | Fluorescence (Elastomeric microfluidic chip) | LOD: 12 μg/mL for CRP; LOD: 30–300 ng/mL for ferritin | 25 min approximately | (20) |
| CRP, tumor necrosis factor α (TNFα), and procalcitonin (PCT) | Serum | Fluorescence (Sensor chip of PMMA) Multiplexed | LOD: 1.265 μg/mL for CRP; LOD: 10 ng/mL for TNFα; LOD: 50 ng/mL for PCT | 25 min approximately | (21) |
| Prostate specific antigen (PSA) | Serum | Voltammetry (Electrochemical immunosensor in plastic disposable cartridge) | LOD: 20 pg/mL | 20 min | (22, 23) |
| Cardiac troponin I (cTnI) | Serum | Magnetic signal (plastic disposable cartridge) | LOD: 10 pg/mL | 15 min | (24) |
| Method                                                     | Sample Type | Assay Type                           | LOD (Concentration) | Incubation Time (min) |
|------------------------------------------------------------|-------------|-------------------------------------|---------------------|-----------------------|
| Microarrays (multiplex)                                    | Plasma      | Microfluidic fluorescence           | LOD: 0.35 ng/mL for CRP | 35 min                |
|                                                            |             |                                    | LOD: 0.08 ng/mL for IL-6 |                       |
|                                                            |             |                                    | LOD: 1.01 ng/mL for PCT  |                       |
| 12 tumor markers (PSA and 11 cytokines)                    | Plasma      | Fluorescence                        | LOD: ~30pM          | 10 min                |
| PSA, TNFα, IL-6, and IL-23                                | Protein     | Bright white “light-emitting diode” (LED) | 3.4 ng/mL for PSA |                       |
|                                                            |             | Multiplexed                         | LOD: 0.1 ng/mL for TNFα, IL-6, and IL-23 |                       |
| Tumor markers (cancer antigens CA 153, CA 125, CA199, and carcinoembryonic antigen: CEA) | Serum       | Voltammetry (Electrochemical immunosensor) | Detectable linear ranges: 0.42–80 U/mL for CA 153 | <5 min                |
|                                                            |             |                                    | 0.5–65 U/mL for CA 125 |                       |
|                                                            |             |                                    | 0.8–75 U/mL for CA 199 |                       |
|                                                            |             |                                    | 0.8–46 ng/mL for CEA  |                       |
| Anti-hepatitis C virus (anti-HCV) antibodies (HCV core and nonstructural 4 antigen [NS4]) | Artificial targets and human serum | Fluorescence | LOD: 10 ng/mL for anti-HCV core | 14 min                |
|                                                            |             |                                    | LOD: 50 ng/mL for NS4  |                       |
| CRP                                                        | Saliva (1000-fold dilution) | Fluorescence | LOD: 10 pg/mL | 10 min                |
|                                                            | Saliva      | Fluorescence                        | LOD: From 8 pM for IL-8 | Incubation: 2 h      |
|                                                            |             |                                    | to 469 pM for (VEGF) | Assay: 30 min         |
| Other methods                                              |             |                                    | LOD: 0.2 ng/mL       | 2 h                   |
| Cardiac troponin T (cTnT)                                 | Serum       | Amperometric (Electrochemical immunosensor) | Linear range: 0.1–10 ng/mL | (38)                  |
|                                                            |             |                                    | LOD: 0.2 ng/mL       |                       |
| Tumor markers (PSA, CEA, and AFP)                          | Serum       | Multiplexed silicon field-transistor (Si-FET) | Detection quantitative: from 0.2 to 114 ng/mL | 20 min                |
|                                                            |             |                                    | LOD: 0.39 ng/mL     |                       |
|                                                            |             | Quartz crystal microbalance e sensor | Detection range: 0.39–200 ng/mL | 8 min                 |
|                                                            |             |                                    | LOD: 0.02 ng/mL     |                       |
|                                                            |             |                                    | Linear range: 0.1–10 ng/mL |                       |
|                                                            |             |                                    | LOD: 0.39 ng/mL     |                       |
|                                                            |             |                                    | Linear range: 0.1–10 ng/mL |                       |
|                                                            |             |                                    | LOD: 3 μg/mL        |                       |
|                                                            |             |                                    | Linear range: 0–260 μg/mL |                       |
|                                                            |             |                                    | LOD: 160 ng/mL      |                       |
|                                                            |             | Noncompetitive immunoassay          | LOD: 0.1 ng/mL      |                       |
|                                                            |             | Fluorescence                        | LOD: 0.1 ng/mL      |                       |
|                                                            |             |                                    | LOD: 0.39 ng/mL     |                       |
|                                                            |             | Homogeneous fluoroimmunoassay       | LOD: 0.02 ng/mL     |                       |
|                                                            |             |                                    | Linear range: 0.1–10 ng/mL |                       |
|                                                            |             |                                    | LOD: 2.5 nM         |                       |
|                                                            |             | GoldBio strip reader after aptamers binding | LOD: 160 ng/mL | 2 min                 |
|                                                            |             |                                    | LOD: 160 ng/mL      |                       |
|                                                            |             |                                    | LOD: 0.1 ng/mL      |                       |
|                                                            |             |                                    | LOD: 0.39 ng/mL     |                       |
|                                                            |             | Homogeneous fluoroimmunoassay       | LOD: 0.02 ng/mL     |                       |
|                                                            |             |                                    | Linear range: 0.1–10 ng/mL |                       |
|                                                            |             |                                    | LOD: 2.5 nM         |                       |
|                                                            |             | GoldBio strip reader after aptamers binding | LOD: 160 ng/mL | 2 min                 |
|                                                            |             |                                    | LOD: 160 ng/mL      |                       |
|                                                            |             |                                    | LOD: 0.1 ng/mL      |                       |
|                                                            |             |                                    | LOD: 0.39 ng/mL     |                       |
|                                                            |             | Homogeneous fluoroimmunoassay       | LOD: 0.02 ng/mL     |                       |
|                                                            |             |                                    | Linear range: 0.1–10 ng/mL |                       |
|                                                            |             |                                    | LOD: 2.5 nM         |                       |
|                                                            |             | GoldBio strip reader after aptamers binding | LOD: 160 ng/mL | 2 min                 |

(Continued)
immunosorbent assay (ELISA), and it could be carried out in a shorter time (25 min). In addition to raw serum, microcapillary systems allow for the use of diluted serum and cerebrospinal fluid in the detection of CRP within 10 min.\textsuperscript{16}

The use of microcapillary arrangements has driven some researchers to use polydimethylsiloxane (PDMS) as an elastomeric support. PDMS is a soft organic silicon polymer that is widely used for cheap microfluidic devices, and some of these supports contain multiple channels. Gervais et al\textsuperscript{17} designed a capillary-driven microfluidic chip built on PDMS, which was capable of analyzing CRP from human serum using a fluorescence microscope. This method allowed the detection of 10 ng/mL of CRP in serum in a single step within less than 3 min. For smaller sample amounts, this device had a capillary pump that permitted slower sample speed. In this way, a 1 ng/mL concentration was detected by slowing the detection process to 14 min.

In a similar approach, Hosokawa et al\textsuperscript{18} produced a PDMS microchip with no pump. Instead, channels were filled with liquid as a consequence of the pressure difference produced by degassing. They tested the method for the detection of human CRP and rabbit IgG (they also tried a competitive method for the latter) and achieved limits of detection of 0.21 nM (0.21 fmole) and 0.42 nM, respectively. A number of analytes can be measured using these microfluidic systems, such as vascular endothelial growth factor (VEGF),\textsuperscript{19} ferritine,\textsuperscript{20} or CRP.\textsuperscript{20} An alternative method used PDMS microchips with affinity microcolumns to isolate and assess Hb A1c. However, for this method, the Ag-Ab (antigen-antibody) mix had to be incubated for 1 h and 37°C prior to detection.

Although PDMS provides a good support for miniaturized POC applications, some authors prefer to use more rigid supports such as poly(methyl methacrylate) (PMMA). This is the case of the work carried out by Kramer et al,\textsuperscript{21} who achieved simultaneous determination of 3 inflammation and sepsis parameters: TNFα, PCT, and CRP from human serum. This method involved an incubation step that took 20 min.

In addition to fluorescence detection, there are other approaches to improving the efficiency of LFI biosensors. One of these alternatives includes the use of quantum dots (a particular kind of semiconductors that can produce signals with good sensitivity). An example of this strategy can be found in the work by Liu et al.\textsuperscript{22} They used the classic LFI technique with electrochemical immunosensors, where the conjugated antibody was marked with (CdS/ZnS) quantum dots. They obtained electrochemical measurements of tumor marker PSA. A similar method was also used by Lin et al\textsuperscript{23} who achieved a limit of detection of 0.02 ng/mL and

| Tested target | Relevance of sample* | Detection strategy | Sensitivity/Limit of detection (LOD)† | Timeframe | Ref. |
|---------------|----------------------|--------------------|--------------------------------------|-----------|-----|
| Generation of thrombin and other coagulation activators | Whole blood and plasma | Amperometric (Substrate cleaved for coagulation activation) | LOD: 0.4 U/ml thrombin | 15-20 min | (44) |
| Albumin | Urine | Visual (Spot test with erythrosin B) | LOD: 0.5 mg/mL | 5 min | (45) |
| a-amilase | Saliva | Reflectance with LED device (Test strip) | LOD: 10 μg/mL Linear range: 10–132 kU/L at 37°C | 0.5 min | (47) |

*We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample.
†Some studies focus on LOD and others on sensitivity. In either case, the values may depend on specific experimental conditions, and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters.
good reproducibility (with a relative standard deviation of 6.4%) using a serum sample. An alternative to the quantum dots could be the use of markers with magnetic properties. Xu et al.\textsuperscript{24} explored this option for the detection of very small amounts (0.01 ng/dL) of cardiac marker cTnI (cardiac troponin I) in serum. They used superparamagnetic nanobeds as markers for the conjugated antibody and they could measure the magnetic signal produced by sandwich type superparamagnetic complexes.

**Microarrays.** Microarrays consist of multiple microscopic detection spots placed on a chip, and they are suitable for POC applications due to their small dimensions and capacity for multiplexing. The work by Kemmler et al.\textsuperscript{25} is an example of an application using this set-up. These authors used a compact microarray system for the determination of inflammation and sepsis markers CRP, IL-6, and PCT in plasma. The system contained a fluidic apparatus work with small volume samples. Fan et al.\textsuperscript{26} used this principle to carry out a simultaneous analysis on 12 plasma proteins (PSA and 11 cytokines). The detection was performed using an integrated barcode designed with polydimethylsiloxane (PDMS) on glass and containing a multichannel matrix capable of measuring plasma proteins in situ. These channels contained DNA oligomers that could bind specific sequences from DNA-tagged antibodies and plasma proteins that could be captured between 2 antibodies. Prior to this step, plasma had to be separated from blood cells right on the chip. Results were obtained within 10 min from a single blood drop.

Schroeder et al.\textsuperscript{27} developed a similar technique for PSA, TNFα, IL-6, and IL-23; and Wu et al.\textsuperscript{28} also developed an electrochemical immunosensor to simultaneously determine tumor markers (cancer antigens) CA153, CA 125, CA 199, and CEA (carcinoembryonic antigen). In these microarrays, immobilized gold nanoparticles had peroxidase-tagged antibodies, which provided a direct electrochemical response. When the antigen bonded to the antibodies and immunocomplexes formed, a signal reduction was observed in relation to the steric hindrance of the peroxidase. Ember et al.\textsuperscript{29} also described the preparation of a platform that contained a microarray for the detection of hepatitis C antibodies by fluorescence. They obtained analytical results within 30 min.

In saliva, Christodoulides et al.\textsuperscript{30} could detect 10 pg/mL CRP in 1000-fold diluted samples. Additionally, Blicharz et al.\textsuperscript{31} could detect 10 proteins (VEGF, epidermal growth factor [EGF], interferon-inducible [IP-10], IL-8, monocyte chemoattractant protein-1 [MCP-1], tissue inhibitor of matrix metalloproteinase-1 [Timp-1], regulated upon activation, normal T cell expressed and secreted [RANTES], macrophage inflammatory protein-beta [MIP-1 β], eotaxin-2, and IL-6) related to asthma attacks, and Floriano et al.\textsuperscript{32} detected 21 proteins related to myocardial stroke, showing the multiplexing potential of microarrays.

**Aptamers.** Aptamers are *in vitro*-evolved nucleic acid molecules that are capable of binding specific target molecules or cells,\textsuperscript{33-35} and it is possible to use them for the analysis of protein samples. This case is demonstrated in a recent article where they used aptamers in a dry-reagent strip application for the detection of thrombin from human plasma.\textsuperscript{36} Aptamers substituted for antibodies in the test and control zones. A set of aptamers was labeled with gold nanoparticles, which was shown to have equal specificity and greater sensitivity to bench top equivalent methods. The authors obtained a limit of detection of 2.5 nM and good linearity in the 5–100 nM range for thrombin. Similarly, Liu et al.\textsuperscript{37} detected whole Ramos cancer cells with aptamers, showing that this molecular tool is very versatile for a wide range of analytes because they can be used even in the absence of specific structural knowledge about the target.

**Other methods.** Silva et al.\textsuperscript{38} used anti-cTnT (cardiac Troponin T) Ab-containing streptavidin-conjugated microspheres, which they incubated with serum cTnT samples for 1 h and followed with another hour with Ab-conjugated HRP (horseradish peroxidase). After a wash and addition of H₂O₂, they could measure an amperometric signal. Kim et al.\textsuperscript{39} also measured an electric signal to analyze tumor markers PSA, CEA, and alpha fetoprotein (AFP) simultaneously. They used silicon field-effect-transistor (Si-FET); a kind of transistor that uses the electric field itself to alter the conductivity of the material) sensors that contained antibodies for each of the tumor markers from serum. A similar method was used by Uludag et al.\textsuperscript{40} with quartz crystal microbalance sensors to analyze PSA and PSA-α1-antichymotrypsin (ACT) complexes. The method described by Ross et al.\textsuperscript{7} using piezoelectric sensors to measure concentrations of hCG and TSH in blood, plasma, and serum, falls in a similar category, and they achieved a low limit of detection (28 pg/mL), with a good linearity in the reference range (80–800 pg/mL).

Some applications use magnetic particles as a convenient way of separating target proteins such as CRP from the medium, as well as a way to detect proteins based on their magnetic properties Ibraimi et al.\textsuperscript{41} This analysis could be done with 4 μL of whole blood samples within 5 min and with a good correlation to reference
clinical immunoassays (magnetic immunoassay [MIA] and turbidimetric). Similarly, Tarkkinen et al.42 developed a single-step noncompetitive assay for the same protein, measuring the fluorescence from an organic complex of Europium conjugated to the detection Ab. Kupstas et al.13 also used a similar complex as a donor for FRET, and allophycocyanin (APC) as the acceptor. These authors adapted a reference homogeneous fluoroimmunoassay into a commercial plate-reader system (KRYPTOR) to achieve miniaturization and to reduce assay costs. They achieved better sensitivity and limit of detection than the standard plate-reader method.

It is also possible to carry out specific analyses without using antibodies. Thuerlemann et al.44 monitored the formation of thrombin as it cleaved a specific substrate described below as an exploration of current research directions.

Correction.

The limit of detection was established at 10 m\( \mu \)g/mL. Additionally, hand-held monitoring of the sympathetic nervous system could also be carried out using a reactive strip to measure  \( \alpha \)-amilase in saliva Yamaguchi et al.37

Wang et al.48 used a sandwich-type ELISA on a microchip for the detection of ovary cancer marker human epididymis protein 4 (HE4). The detection antibody was labeled with horseradish peroxidase so that when TMB (3,3‘,5,5‘-tetramethylbenzidine, a chromogenic substance) was added, the resulting blue color could be recorded in a system coupled to a cell phone. When diagnostic specificity and sensitivity of this device were compared with microplate conventional immunoassays, they observed that specificity is 90% in both cases and sensitivity was lower than for the microplate assay (94.7% for the microplate and 84.2% for the chip).

### ANALYSIS OF NUCLEIC ACIDS

Although proteins are a common target for the POC analyses, specific nucleic acid analyses can also contribute to the characterization of biological samples (see Table II). One of the main challenges in the analysis of nucleic acids for clinical, forensic, and other applications is the small amount of sample. To read a sufficient signal in the corresponding instrument, the amount of sample, the signal intensity (but not the noise), or both need to be increased. Some interesting methods that can be used for sample and signal amplification are described below as an exploration of current research direction.

**Signal amplification.** Some authors focus on the amplification of the detection signal instead of the sample. This is the approach of Wei et al.49, who used a hairpin (hp) RNA molecule coupled with horseradish peroxidase to obtain specific and very sensitive detection of endogenous IL-8 mRNA, a proposed salivary biomarker for oral cancer. The hp molecule contained a sequence complementary to the target mRNA sequence. Absent the target mRNA, the hp was self-annealed and the horseradish peroxidase was too close to the solid support of the hp probe to interact with its substrate. However, in the presence of the target mRNA, the hp hybridized with it, changing its conformation and moving the peroxidase away from the solid support. As a result, the peroxidase, free from steric hindrance, could interact with its substrate and produce a measurable electrochemical signal.

**Isothermal amplification.** In spite of attempts aimed at increasing detection signal, given the availability of the polymerase chain reaction (PCR), amplification of DNA is still a useful strategy. However, even with the high sensitivity and specificity of PCR-based methods, they have drawbacks such as the dependence on a thermocycler, which can increase the cost and complexity of miniaturized portable devices. As a result, different strategies have been proposed to amplify samples without using a thermocycler. One of these strategies is the loop-mediated isothermal amplification (LAMP) of DNA.50 This technique relies on strand displacement by a DNA polymerase and on the appropriate design of primers (4 primers that can bind in 6 distinct sequences) to amplify target sequences at a constant temperature (~60°C) with high selectivity. Based on this principle, Bearinger et al.51 developed a prototype of a small device capable of analyzing swab-collected samples in ~90 min. They could detect ~17 copies of methicillin resistant *Staphylococcus aureus* (MRSA) genomic DNA and foot-and-mouth disease virus (FMDV) from an epithelial homogenate in 100 \( \mu \)L of reaction volume. They used a simple colorimetric detection system based on the detection of free Mg\(^{2+}\). The method is based on the principle that the concentration of this ion diminishes as it binds to the pyrophosphate that is released in the amplification reaction. The versatility of this method also permits applications that use reverse transcription.52

Fang et al.53 also used a LAMP system, but in this case, they developed a multiplex gene assay using a microfluidic set-up with 10 microchambers connected to 1 microchannel per chamber. The microchannels had low mass-transfer coefficients to prevent cross contamination among different microchambers and, in addition to the direct visualization by the white precipitate...
Table II. Summary of the latest works integrating different POC instruments to analyze nucleic acids

| Tested target                                                                 | Relevance of sample*                        | Detection strategy                                                                                       | Sensitivity / Limit of detection (LOD)† | Timeframe | Ref. |
|------------------------------------------------------------------------------|---------------------------------------------|-------------------------------------------------------------------------------------------------------|----------------------------------------|-----------|------|
| IL-8 mRNA (proposed salivary marker for oral cancer)                         | Clinical saliva samples                    | Signal amplification taking advantage of steric self-hindrance of a hairpin probe that prevents horseradish peroxidase to reach its substrate and produce and electrochemical signal | LOD: 0.4 fM                            | 1 min     | (49) |
| Methicillin resistant Staphylococcus aureus (MRSA) genomic DNA and foot-and-mouth disease virus (FMDV) | Swab collected sample                      | Loop-mediated isothermal amplification (LAMP) and colorimetry                                          | LOD: 17 copies in 100 µL of reaction volume | ~90 min   | (51) |
| Nervous necrosis virus RNA                                                    | Infected biological samples                | Magnetic purification, reverse-transcript LAMP (RT-LAMP) and slab gel electrophoresis                    | LOD: 100 fg cDNA                       | 60 min    | (52) |
| Flu viruses including influenza A H1N1                                       | Clinical samples                           | Visual and fluorimetric detection on multiplex microfluidic LAMP (μm-LAMP) with 10 microchambers       | LOD: 10 copies/ µL in 2 µL             | 0.5 h     | (53) |
| Genomic DNA of N. gonorrhoeae and S. aureus (MRSA)                          | Laboratory preparations of N. gonorrhoeae and S. aureus | Fluorescence after helicase dependent amplification (HAD) at 65°C                                      | LOD: 250 pg genomic MRSA-DNA (5 × 10⁵ S. aureus cells) LOD: 1 ng of pivNG gene (1.32 × 10⁵) N. gonorrhoeae cells | ~145 min  | (54) |
| RNA from Bacillus anthracis                                                   | RNA purified from a laboratory strain      | Lateral flow microarray (LFM) after nucleic acid sequence based amplification (NASBA)                  | LOD: 250 fg (2–3 B. anthracis cells)   | ~60 min   | (56) |
| Cryptosporidium parvum oocysts                                               | Purified total mRNA from C. parvum         | Oligonucleotide-gold nanoparticles after amplification of heat shock proteins (HSP)                    | LOD: 5000 C. parvum oocysts           | ~2–3 h    | (57) |
| pUC18                                                                        | pUC18 amplicon                             | Sanger sequencing                                                                                      | LOD: 1 fmole                           | ~30–35 min| (58) |
| Single nucleotide variations/ interaction of DNA with polymerase             | Synthetic oligonucleotides                | Nanopore analysis                                                                                     | LOD: 100 fmole                         | ~5 min    | (60-63) |

*We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample.
†Some studies focus on LOD and others on sensitivity. In either case, the values may depend on specific experimental conditions and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters.
‡See Table III for PCR applications.
| Tested target                                      | Relevance of sample*            | Sensor          | Device features                                                                 | Sensitivity/Limit of detection (LOD)† | Timeframe                | Ref. |
|---------------------------------------------------|---------------------------------|-----------------|---------------------------------------------------------------------------------|--------------------------------------|--------------------------|------|
| Cyanobacterial 16S rRNA gene (2060-bp) and human anti-α-1-chymotrypsin gene (330-bp) | Test oligos                    | Off the device  | PCR only                                                                        | LOD: 0.5 ng/μL genomic DNA           | 22.5 min (for amplification only) | (72) |
| H1N1 virus                                        | Swab saliva sample              | E-DNA           | MIMED                                                                           | LOD: 10 TCID<sub>50</sub>            | 3.5 h (PCR~150min)       | (68) |
| Influenza A, influenza B, corona virus OC43, and human metapneumovirus | Cloned target viral sequences in plasmid standards | Fluorescence labeling of forward PCR primers | Integrated microdevice for concentration, amplification and multiplex analysis | LOD: 10 copies/reactor | within 2 h | (73) |
| STR<sup>‡</sup>                                    | Cells from a buccal swab sample | optical excitation/ detection module | DNA analysis compatible with CODIS | Sensitivity: 1.15bp | 3.5 h | (74) |
| STR (Y STR ie, STR from the Y chromosome)         | Buccal swab sample              | Fluorescence from fluorescence-labeled primers | Just for stacking capillary electrophoresis (no PCR) | LOD: 25 pg (1:1000 male:female genomic DNA + 15 min. DNase I digestion) | 6 min just the electrophoresis | (75) |
| STR                                               | Biological stains from a mock crime scene | Fluorescence | Real-time PCR in 100mm wafers | LOD: 100 copies for complete DNA profile; sensitivity: 0.8 bp allele typing accuracy | 2.5 h | (69) |
| Determination of monozygous twinning              | Buccal swab sample              | Fluorescence    | microfabricated capillary array electrophoresis (μCAE) | Sensitivity: single base resolution | <30 min | (76) |
| *Escherichia coli* stx1                           | Lab culture                     | Fluorescence reporter probes | Miniature real-time PCR | Minimum amount used: 1.25 ng/μL | Regular real-time PCR | (70) |
| Synthetic test oligo                              | Synthetic test oligo            | Fluorescence of Cy3-labeled probe | Microstructured optical fiber (MOF) | 10 μM (in 10 nL) | <30 min (hybridize and detect) | (77) |
| Methicillin-resistant Staphylococcus aureus (MRSA) | DNA extracted from clinical MRSA isolates | FRET from probes labeled with AlexaFluor 647 reporter dye and BHQ3 quencher dye | PDMS microfluidic system for PCR and fluorescence detection | Used sample containing 11.2 pg of DNA | Regular real-time PCR | (78) |
| DNA | In test buffer | FRET from fluorescein and MGB-NFQ maker-containing primers | Microfluidic device to characterize PCR in aqueous-in-oil droplets and FRET | Minimum used concentration: $3.5 \times 10^{-14}$ ng/mL | Regular real-time PCR (67) |
|---------------------|----------------|-------------------------------------------------|------------------------------------------------------------------|--------------------------------|----------------------------------|
| *Escherichia coli* and *Bacillus* | Lab culture | Electrochemical detection on gold nanoparticles | Thermal lysis, magnetic isolation, asymmetric PCR (one primer more abundant than the other), and detection using silver-enhanced gold nanoparticles | LOD: 0.5 nM genomic DNA; linear between $10^2$–$10^5$ cells/sample | About 3 h (79) |
| Genetic breast cancer markers: estrogen receptor-$\alpha$, plasminogen activator urokinase receptor, epidermal growth factor receptor, and erythroblast leukemia viral oncogene homolog 2 | Test samples | Surface Plasmon Resonance | Multiplex device | LOD: $\sim$3 nM | 90 min (excluding PCR) (66) |
| Hepatitis C virus RNA | Total RNA extracted from clinical samples | Cy3-conjugated oligonucleotide detection probes | Microarray combining protein and nucleic acid detection | LOD: 10 pM | 16 min after PCR (29) |

*We indicate in this column what kind of samples (actual patient samples, synthetic test oligos, etc.) were used to compare them with what could be found in an actual patient sample. Some studies focus on LOD and others on Sensitivity. In either case, the values may depend on specific experimental conditions and these values should be taken as merely indicative. Samples are usually applied in volumes of a few microliters. Short tandem repeats (STR) can be used for identification in forensic science, a field that could also benefit from new POC applications.*
formed by Mg$^{2+}$ and pyrophosphate, they added a fluorescent dye to obtain the positive signal. They called this system mLAMP (multiplex microfluidic LAMP), and it allowed them to detect as few as 10 copies/µL of the target sequence in 2 µL quantities of sample within 30 min. In this study, they used flu viruses to test the device, and they were able to detect the seasonal influenza A H1N1 virus from clinical samples.

Another example for the amplification of target nucleic acid sequences without thermocyclers was developed by Andresen et al. They used labeled primers to detect amplified sequences from genomic DNA of laboratory preparations of N. gonorrhoeae and S. aureus.

Nucleic acid sequence based amplification (NA SBA) is a similar strategy that can be useful for point-of-care analytics. This technique relies on the T7 RNA polymerase activity, which can catalyze the synthesis of RNA from dsDNA, performing a role similar to what the helicase does in HDA. Using this principle in miniaturized lateral flow chromatography devices, Carter et al.56 detected RNA from pathogens such as Bacillus anthracis in 10 µL volumes, achieving subfemtomole limit of detection. They could detect RNA from as few as 2 B. anthracis cells within 120 s after sample preparation and amplification. In this case, they carried out the detection of laboratory preparations of the bacillus by hybridizing them to oligonucleotides attached to dyed microspheres. The separation was carried out in lateral flow chromatography microarrays (thus named LFM), which allow the determination of analytes without the use of fluorescence detection systems and provide the ground for multiplexing.

**Alternative methods.** There are some specific methods for the detection of nucleic acids that deserve a separate mention due to their originality. One of these methods involves the use of heat shock proteins (HSP). More specifically, Javier et al.57 developed this strategy to detect mRNA targets derived from Cryptosporidium parvum oocysts using oligonucleotide-gold nanoparticles. By incubating the oocysts at 42°C for 20 min, they induced the synthesis of the mRNA for HSPs and they purified them with magnetic beads that were coupled with oligo-dT. They detected the mRNA for HSP70 using gold nanoparticles coupled with oligonucleotides specific to their target mRNA. These gold nanoparticles facilitate the formation of aggregates in the presence of the target mRNA, and they can be detected by simple colorimetric changes in to the surface plasmon resonance (SPR). This detection method is based on the distortion that adsorbed analytes produce on measurable electron oscillations on the surface of the gold particle, and it is common among lab-on-a-chip microdetection devices. The use of HSP mRNA is a clever way of achieving nucleic acid amplification with low material requirements. However, oocysts need to be alive so that they can respond to the heat shock, a factor that must be taken into account for future applications and extensions of this method.

The specific interactions of nucleic acids are based on their base sequence. Hybridization with appropriate probes is an indication of this specificity. However, the most accurate method for the identification of a given nucleic acid is sequencing. In this sense, it is remarkable that the traditional Sanger sequencing method was implemented by Blazej et al.58 who were able to complete Sanger sequencing from only 1 fmole of DNA template. These authors could sequence up to 556 continuous bases with 99% accuracy, demonstrating read lengths required for de novo sequencing of human and other complex genomes.

In their work, Blazej et al.58 implemented a classical sequencing scheme that included dye-terminator sequencing and laser-induced fluorescence detection, and they were able to obtain sequence data within 35 min with a small circular bioprocessor that was 100 nm in diameter. However, as described in the next section, faster sequencing technology may become available in the future.

**Nanopore analysis.** As stated in the previous section, sequencing nucleic acids from analytical samples is one of the most direct ways of characterizing this molecule. Since its introduction in 1996 as a method for the analysis of nucleic acids,59 nanopore technology has experienced substantial progress to the point where it is currently possible to obtain sequence information on single nucleic acid molecules60 as well as on complexes formed by nucleic acids and proteins.60-63 These analyses are based on the principle that nucleic acids go through nanoscopic pores by electrophoresis. The dimensions of these pores are such that when nucleic acids go through, they cover most of the pore area. The aqueous buffer in which the pore is immersed contains ions that produce a measurable electric current. When the nucleic acids traverse the pore, a blockade in the current can be detected and, on average, this blockade has different properties depending on the specific characteristics (including base sequence) of the analyte that is going through. Nucleic acids are driven to the pore by the electric voltage as soon as they are added to the detection solution and the measurements can be carried out.
within 5 min for a single nucleic acid sample. Given these properties, it is likely that this technology can be used for sequencing applications in the near future.

Currently, the most sensitive nanopores are formed with α-hemolysin toxins inserted in lipid membranes. However, there are technical difficulties associated with the formation and maintenance of such pores and this factor is encouraging research on solid state nanopores, for which sensitivity is gradually improving. Solid state nanopores are more durable than biological ones, but their sensitivity is smaller. Thus, some researchers are working to combine the best features of both types of nanopores by coating the metallic surface of solid nanopores with lipids. This sequencing approach has great potential to develop POC sequencing instruments due to the small dimensions of the pore and the small analyte amounts required.

**PCR.** In spite of the multiple alternatives presented so far, PCR still remains an important method for target nucleic acid sequence amplification, a technique that helps in the acquisition of a good signal and in the efficient and specific detection of analytic targets. Table III summarizes some of the latest works dealing with different steps in the sample preparation, PCR-amplification, and detection of biological samples on solid supports as a step toward the fabrication of miniaturized POC instruments. In this area, technological improvements may involve variations in electrode preparation or control software.

Many of these works involve the fabrication of solid supports with micro-electro-mechanical systems (MEMS) or magnetic integrated microfluidic electrochemical detectors (MIMED), to achieve temperature control or to perform all steps of the analysis, respectively.

Instead of the reverse-transcriptase-PCR used by some of the devices mentioned before, some of the POC instruments capable of PCR perform real-time PCR. In this sense, it is worth mentioning the work by Lee et al who compared conventional real-time PCR machines with real-time PCR chips. They concluded that PCR chips, which are mostly made using MEMS, have the advantage of their compact size, low sample volume (in the nanoliter range), and their short analysis time (which can be as short as 10 s per PCR cycle and 370 s for the whole quantification process). However, it seems that these devices still have room to improve in terms of detection limit, quantification uncertainties, and melting analysis ability.

**CONCLUSION**

In conclusion, there are many devices that are currently being designed to carry out POC analyses. Their aim is to detect and quantify proteins and nucleic acid markers for a variety of health conditions: from infectious agents such as the influenza virus, to conditions such as breast, ovary, or bladder cancers. Many of these devices still need some work to become functional parts of a complete POC analysis device. However, given the fast progress in the field and the large number of research groups involved, we believe that remaining issues will be soon overcome, and portable and economical POC devices that include the features described in this article will become commercially available in the near future.

The authors thank Kate Chabarek for her editing suggestions on the format and content of this manuscript.

**REFERENCES**

1. Fujisawa T, Kaneko T, Kumagai T, et al. Evaluation of urinary rapid test for Helicobacter pylori in general practice. J Clin Lab Anal 2001;15:154–9.
2. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA 2005;293:810–6.
3. Posthuma-Trumpie GA, Korf J, van Amerongen A. Lateral flow (immuno) assay: its strengths, weaknesses, opportunities and threats. A literature survey. Anal Bioanal Chem 2009;393:569–82.
4. Pfafflin A, Schleicher E. Inflammation markers in point-of-care testing (POCT). Anal Bioanal Chem 2009;393:1473–80.
5. Friess U, Stark M. Cardiac markers: a clear cause for point-of-care testing. Anal Bioanal Chem 2009;393:1453–62.
6. Healy DA, Hayes CJ, Leonard P, McKenna L, O’Kennedy R. Biosensor developments: application to prostate-specific antigen detection. Trends Biotechnol 2007;25:125–31.
7. Ross SA, Carter TJN. Piezofilm sensors in point-of-care testing devices. In: Price CP, St John A, Kricka LJ, eds. Point-of-care testing needs opportunity and innovation. Washington, DC: American Association for Clinical Chemistry, 2010:121–9.
8. Ahn JS, Choi S, Jang SH, et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. Clinica Chimica Acta 2003;332:51–9.
9. Meagher RJ, Hatch AV, Renzi RF, Singh AK. An integrated microfluidic platform for sensitive and rapid detection of biological toxins. Lab on a Chip 2008;8:2046–53.
10. Herr AE, Hatch AV, Throckmorton DJ, et al. Microfluidic immunoassays as rapid saliva-based clinical diagnostics. Proc Nat Acad Sci U S A 2007;104:5268–73.
11. Clark TJ, McPherson PH, Buechler KF. The triage cardiac panel. Point of Care 2002;1:42–6.
12. Dupuy AM, Lehmann S, Cristol JP. Protein biochip systems for the clinical laboratory. Clin Chem Lab Med 2005;43:1291–302.
13. Warsinke A. Point-of-care testing of proteins. Anal Bioanal Chem 2009;393:1393–405.
14. Laskowitz DT, Kasner SE, Saver J, Remmel KS, Jauch EC, Grp BS. Clinical Usefulness of a Biomarker-Based Diagnostic Test for Acute Stroke The Biomarker Rapid Assessment in Ischemic Injury (BRAIN) Study. Stroke 2009;40(1):77–85.
15. Bhattacharyya A, Klapperich CM. Design and testing of a disposable microfluidic chemiluminescent immunoassay for disease biomarkers in human serum samples. Biomed Microdevices 2007;9:245–51.
16. Peoples MC, Karnes HT. Microfluidic capillary system for immunoassay separations of C-reactive protein in human serum and cerebrospinal fluid. Anal Chem 2008;80:3853–8.

17. Gervais L, Delamarche E. Toward one-step point-of-care immunodiagnostics using capillary-driven microfluidics and PDMS substrates. Lab on a Chip 2009;9:3330–7.

18. Hosokawa K, Omata M, Sato K, Maeda M. Power-free sequential injection for microchip immunoassay toward point-of-care testing. Lab on a Chip 2006;6:236–41.

19. Lin DH, Taylor CR, Anderson WF, Scherer A, Kartalov EP. Internally calibrated quantification of VEGF in human plasma by fluorescence immunoassays in disposable elastomeric microfluidic devices. J Chromatography B 2010;878:258–63.

20. Kartalov EP, Lin DH, Lee DT, Anderson WF, Taylor CR, Scherer A. Internally calibrated quantification of protein analytes in human serum by fluorescence immunoassays in disposable elastomeric microfluidic devices. Electrophoresis 2008;29:5010–6.

21. Kramer PM, Kess M, Kremmer E, Schulte-Hostede S. Multiplexed immunoassays based on superparamagnetic nanobeads as labels for rapid quantitative detection of cardiac troponin I. Mater Sci Eng C 2009;29:702–5.

22. Liu GD, Lin YY, Wang J, Wu H, Wai CM, Lin YH. Disposable electrochemical immunosensor diagnosis device based on nanoparticle probe and immunochromatographic strip. Anal Chem 2007;79:7644–53.

23. Lin YY, Wang J, Liu GD, Wu H, Wai CM, Lin YH. A nanoparticle label/imunochromatographic electrochemical biosensor for rapid and sensitive detection of prostate-specific antigen. Biosens Bioelectron 2008;23:1659–65.

24. Xu QF, Xu H, Gu HC, Li JB, Wang YY, Wei M. Development of lateral flow immunoassay system based on superparamagnetic nanobeads as labels for rapid quantitative detection of cardiac troponin I. Mater Sci Eng C 2009;29:702–7.

25. Kemmler M, Koger B, Sulz G, et al. Compact point-of-care system for clinical diagnostics. Sensors Actuators B Chem 2009;136:692–5.

26. Fan R, Vermesh O, Srivastava A, et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood. Nat Biotechnol 2008;26:1373–8.

27. Schroeder H, Adler M, Gerigk K, Muller-Chorus B, Gotz F, Schroeder H, Adler M, Gerigk K, Muller-Chorus B, Gotz F. Monitoring thrombin generation using microchip ELISA to detect ovarian cancer HE4 biomarker. Clin Chim Acta 2009;396:210–5.

28. Wu J, Yan YT, Yan F, Ju HX. Electric field-driven strategy for multiplexed detection of protein biomarkers using a disposable reagentless electrochemical immunosensor array. Anal Chem 2008;80:6072–7.

29. Emir S, Suulje S, Ross AJ, et al. Fast DNA and protein microarray test for the diagnosis of hepatitis C virus infection on a single platform. Anal Bioanal Chem 2011;401:2549–59.

30. Christodoulides N, Mohanty S, Miller CS, et al. Application of microchip assay system for the measurement of C-reactive protein in human saliva. Lab on a Chip 2005;5:261–9.

31. Blicharz TM, Siqueira WL, Helmerhorst EJ, et al. Fiber-optic microsphere-based antibody array for the analysis of inflammatory cytokines in saliva. Anal Chem 2008;81:2106–14.

32. Floriano PN, Christodoulides N, Miller CS, et al. Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem 2009;55:1530–8.

33. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Ann Rev Biochem 1999;68:611–47.

34. Nimjee SM, Rusconi CP, Sullenger BA. Aptamers: an emerging class of therapeutics. Palo Alto: Annual Reviews. Ann Rev Med 2005;56:555–83.

35. Fang XH, Tan WH. Aptamers generated from cell-SELEX for molecular medicine: a chemical biology approach. Acc Chem Res 2010;43:48–57.

36. Xu H, Mao X, Zeng QX, Wang SF, Kawde AN, Liu GD. Aptamer-functionalized gold nanoparticles as probes in a dry-reagent strip biosensor for protein analysis. Anal Chem 2009;81:669–75.

37. Liu GD, Mao X, Phillips JA, Xu H, Tan WH, Zeng LW. Aptamer-nanoparticle strip biosensor for sensitive detection of cancer cells. Anal Chem 2009;81:10013–8.

38. Silva SVM, Cavalcanti IT, Mattos AB, Moura P, Sotomayor MDT, Dutra RF. Disposable immunosensor for human cardiac troponin T based on streptavidin-microsphere modified screen-printed electrode. Biosens Bioelectron 2010;26:1062–7.

39. Kim A, Ah CS, Park CW, et al. Direct label-free electrical immuno-nodetection in human serum using a flow-through-apparatus approach with integrated field-effect transistors. Biosens Bioelectr 2010;25:1767–73.

40. Udulug Y, Tothill IE. Development of a sensitive detection method of cancer biomarkers in human serum (75%) using a quartz crystal microbalance sensor and nanoparticles amplification system. Talanta 2010;82:277–82.

41. Braimi F, Krid D, Lu M, Hansson LO, Krid K. Rapid one-step whole blood C-reactive protein magnetic permeability immunoassay with monoclonal antibody conjugated nanoparticles as super-paramagnetic labels and enhanced sedimentation. Anal Bioanal Chem 2006;384:651–7.

42. Tarkinen P, Palenius T, Lovgren T. Ultrarapid, ultrasensitive one-step kinetic immunoassay for C-reactive protein (CRP) in whole blood samples: measurement of the entire CRP concentration range with a single sample dilution. Clin Chem 2002;48:269–77.

43. Kupstat A, Kamke MU, Hildebrandt N. Toward sensitive, quantitative point-of-care testing (POCT) of protein markers: miniaturization of a homogeneous time-resolved fluoroimmunoassay for prostate-specific antigen detection. Analyst 2011;136:1029–35.

44. Thauerleman C, Haebert I, Alberio L. Monitoring thrombin generation by electrochemistry: development of an amperometric biosensor screening test for plasma and whole blood. Clin Chem 2009;55:505–12.

45. Kaneko E, Yasuda H, Higurashi A, Yoshimura H. Spot test of urinary protein using erythrosin B and a membrane film. Analyst 2010;135:1564–8.

46. Kouri T, Nokelainen P, Pelkonen V, Kosaka H, Saeger B. Evaluation of the ARKRAY AUtion Eleven reflectometer in detecting microalbuminuria with AUtion Screen test strips and proteinuria with AUtion Sticks 10PA strips. Scandinavian J Clin Lab Invest 2009;69:52–64.

47. Yamaguchi M, Deguchi M, Wakasugi J, et al. Hand-held monitor of sympathetic nervous system using saliva amylase activity and its validation by driver fatigue assessment. Biosens Bioelectron 2006;21:1007–14.

48. Wang SQ, Zhao XL, Khirami I, et al. Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care. Lab on a Chip 2011;11:3411–8.

49. Wei F, Wang JH, Liao W, Zimmermann BG, Wong DT, Ho CM. Electrochemical detection of low-copy number salivary RNA based on specific signal amplification with a hairpin probe. Nucl Acids Res 2008;36:7.

50. Notomi T, Okayama H, Masubuchi H, et al.-loop-mediated isothermal amplification of DNA. Nucl Acids Res 2000;28:7.

51. Beiringer JP, Dugan LC, Baker BR, et al. Development and initial results of a low cost, disposable, point-of-care testing device for pathogen detection. IEEE Trans Biomed Eng 2011;58:805–8.
52. Venkatesan BM, Polans J, Comer J, et al. Lipid bilayer coated Al(2)O(3) nanopore sensors: towards a hybrid biog-

ical solid-state nanopore. Biomed Microdevices 2011;13: 671–82.
53. Fang XE, Chen H, Yu SN, Jiang XY, Kong JL. Predicting viruses accurately by a multiple microfluidic loop-mediated isothermal amplification chip. Anal Chem 2011;83:690–5.
54. Andresen D, von Nickisch-Rosenegk M, Bier FF. Helicase dependent OnChip-amplification and its use in multiplex pathogen detection. Clinica Chimica Acta 2009;403:244–8.
55. Compton J. Nucleic-acid sequence-based amplification. Nature 1991;350:91–2.
56. Carter DJ, Cary RB. Lateral flow microarrays: a novel platform for rapid nucleic acid detection based on miniaturized lateral flow chromatography. Nucl Acids Res 2007;35:11.
57. Javier DJ, Castellanos-Gonzalez A, Weigum SE, White AC, Richards-Kortum R. Oligonucleotide-gold nanoparticle networks for detection of cryptosporidium parvum heat shock protein 70 mRNA. J Clin Microbiol 2009;47:4060–6.
58. Blazej RG, Kumarasen P, Mathies RA. Microfabricated bioprocessor for integrated nanoliter-scale Sanger DNA sequencing. Proc Nat Acad Sci U S A 2006;103:7240–5.
59. Akeson M, Branton D, Kasaniovicz JJ, Brandin E, Deamer DW. Microsecond time-scale discrimination among polyctidylic acid, polyadenylic acid, and polyuridylic acid as homopolymers or as segments within single RNA molecules. Biophys J 1999;77: 3227–33.
60. Gyarfas B, Olasagasti F, Benner S, Garalde D, Lieberman KR, Akeson M. Mapping the position of DNA polymerase-bound DNA templates in a nanopore at 5 angstrom resolution. Ac Nano 2009;3:1457–66.
61. Olasagasti F, Lieberman KR, Benner S, et al. Replication of individual DNA molecules under electronic control using a protein nanopore. Nat Nanotechnol 2010;5:798–806.
62. Garalde DR, Simon CA, Dahl JM, Wang H, Akeson M, Lieberman KR. Distinct complexes of DNA polymerase I (Klenow fragment) for base and sugar discrimination during nucleotide substrate selection. J Biol Chem 2011;286:14480–92.
63. Lieberman KR, Cherf GM, Doody MJ, Olasagasti F, Kolodji Y, Akeson M. Processive replication of single DNA molecules in a nanopore catalyzed by phi29 DNA polymerase. J Am Chem Soc 2010;132:17961–72.
64. He YH, Scheicher RH, Grigoriev A, et al. Enhanced DNA sequencing performance through edge-hydrogenation of graphene electrodes. Adv Funct Mater 2011;21:2674–9.
65. Venkatesan BM, Polans J, Comer J, et al. Lipid bilayer coated Al(2)O(3) nanopore sensors: towards a hybrid biolog-

ical solid-state nanopore. Biomed Microdevices 2011;13: 671–82.
53. Fang XE, Chen H, Yu SN, Jiang XY, Kong JL. Predicting viruses accurately by a multiple microfluidic loop-mediated isothermal amplification chip. Anal Chem 2011;83:690–5.
54. Andresen D, von Nickisch-Rosenegk M, Bier FF. Helicase dependent OnChip-amplification and its use in multiplex pathogen detection. Clinica Chimica Acta 2009;403:244–8.
55. Compton J. Nucleic-acid sequence-based amplification. Nature 1991;350:91–2.
56. Carter DJ, Cary RB. Lateral flow microarrays: a novel platform for rapid nucleic acid detection based on miniaturized lateral flow chromatography. Nucl Acids Res 2007;35:11.
57. Javier DJ, Castellanos-Gonzalez A, Weigum SE, White AC, Richards-Kortum R. Oligonucleotide-gold nanoparticle networks for detection of cryptosporidium parvum heat shock protein 70 mRNA. J Clin Microbiol 2009;47:4060–6.
58. Blazej RG, Kumarasen P, Mathies RA. Microfabricated bioprocessor for integrated nanoliter-scale Sanger DNA sequencing. Proc Nat Acad Sci U S A 2006;103:7240–5.
59. Akeson M, Branton D, Kasaniovicz JJ, Brandin E, Deamer DW. Microsecond time-scale discrimination among polyctidylic acid, polyadenylic acid, and polyuridylic acid as homopolymers or as segments within single RNA molecules. Biophys J 1999;77: 3227–33.
60. Gyarfas B, Olasagasti F, Benner S, Garalde D, Lieberman KR, Akeson M. Mapping the position of DNA polymerase-bound DNA templates in a nanopore at 5 angstrom resolution. Ac Nano 2009;3:1457–66.
61. Olasagasti F, Lieberman KR, Benner S, et al. Replication of individual DNA molecules under electronic control using a protein nanopore. Nat Nanotechnol 2010;5:798–806.
62. Garalde DR, Simon CA, Dahl JM, Wang H, Akeson M, Lieberman KR. Distinct complexes of DNA polymerase I (Klenow fragment) for base and sugar discrimination during nucleotide substrate selection. J Biol Chem 2011;286:14480–92.
63. Lieberman KR, Cherf GM, Doody MJ, Olasagasti F, Kolodji Y, Akeson M. Processive replication of single DNA molecules in a nanopore catalyzed by phi29 DNA polymerase. J Am Chem Soc 2010;132:17961–72.
64. He YH, Scheicher RH, Grigoriev A, et al. Enhanced DNA sequencing performance through edge-hydrogenation of graphene electrodes. Adv Funct Mater 2011;21:2674–9.